SCHEMBL25264679

SCHEMBL25264679

COc1ccc(CN2CCNC(c3ccccc3C(C)C)C2)nc1

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KCNJ1 P48048 6/20 0.38
POLB P06746 1/20 0.35
LTA4H P09960 1/20 0.34
PDE10A Q9Y233 1/20 0.34
HTR1A P08908 1/20 0.34
HTR7 P34969 1/20 0.34
HTR2B P41595 1/20 0.34
SMO Q99835 1/20 0.34
KCNH2 Q12809 1/20 0.34
LMNA P02545 1/20 0.34
KDM4E B2RXH2 1/20 0.34
ALDH1A1 P00352 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
RET P07949 3/20 0.33
HRH3 Q9Y5N1 1/20 0.33
MLNR O43193 1/20 0.33
IKZF2 Q9UKS7 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23944111 1.00 KCNJ1 (0.38) KCNJ1POLBLTA4HPDE10AHTR1A
SCHEMBL25283141 0.86 PDE10A (0.39) KCNJ1POLBLTA4HPDE10AHTR1A
SCHEMBL23943756 0.84 SIGMAR1 (0.47) LTA4H
SCHEMBL25190429 0.84 SIGMAR1 (0.47) LTA4H
SCHEMBL25640478 0.83 LMNA (0.47) POLBLMNAKDM4EALDH1A1L3MBTL1
SCHEMBL25479493 0.81 HRH3 (0.36) POLBLTA4HKDM4EALDH1A1L3MBTL1
SCHEMBL25221452 0.80 TRPV6 (0.44) KCNJ1LTA4HMLNR
SCHEMBL25479115 0.80 RET (0.35) POLBKDM4EALDH1A1L3MBTL1RET
SCHEMBL25268635 0.80 TRPV6 (0.44) KCNJ1LTA4HMLNR
SCHEMBL30414542 0.80 TRPV6 (0.44) KCNJ1LTA4HMLNR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250270210-A1 BCL-2 Inhibitor BEIGENE, LTD. (KY) 2025-08-28 US disclosed
US-12286430-B2 Bcl-2 inhibitor BEIGENE, LTD. (KY) 2025-04-29 US disclosed
US-20240376097-A1 BCL-2 Inhibitor BEIGENE LTD. (KY) 2024-11-14 US disclosed
CN-116969937-A BCL-2 inhibitors 百济神州有限公司 2023-10-31 CN disclosed
CN-116969936-A BCL-2 inhibitors 百济神州有限公司 2023-10-31 CN disclosed
CN-116802179-A BCL-2 inhibitors 百济神州有限公司 2023-09-22 CN disclosed
US-20230159522-A1 BCL-2 INHIBITOR BEONE MEDICINES I GMBH (CH) 2023-05-25 US disclosed
EP-4136084-A1 BCL-2 INHIBITOR BeiGene, Ltd. (KY) 2023-02-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250270210-A1 BCL-2 Inhibitor BCL2, BCL2A1, BCL2L1 KCNJ1 3562/4885POLB 764/4885LTA4H 4756/4885
US-20230159522-A1 BCL-2 INHIBITOR BCL2, BCL2A1, BCL2L1 KCNJ1 3562/4885POLB 764/4885LTA4H 4756/4885
US-20240376097-A1 BCL-2 Inhibitor BCL2, BCL2A1, BCL2L1 KCNJ1 3562/4885POLB 764/4885LTA4H 4756/4885
US-12286430-B2 Bcl-2 inhibitor BCL2, BCL2A1, BCL2L1 KCNJ1 3562/4885POLB 764/4885LTA4H 4756/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.